icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
See also
Décision d'accès précoce
14/11/2024
eNrdWFtv2jAUfudXoDzszUm4rWULVBtrN6RWY7Ro014qkxzAzNiZL5Tu189JYKVToq4GP6yqVAVfvnNif+c75yQ626xofQ1CEs56XsMPvTqwmCeEzXve5OYCnXpn/Vq0xGu8t8ys85tNrx5TLGXPy2b9KWAm/W9Xlx/A7Afh9Wv1iE+XEKtH67Qi1P+E5eIKp9maerTmJKmvQC140vNSrfLReiSVMF7077j4IVMcQxRsR/Znl7ft/fEoyMD+AVVLEJeYzUtBgVlhxloIYGqAFcy5uK/wt2WFTeQYJNcihhFWi5Hga5JAUmpihqkEKyOzu+QaxJqCyoyUggfLeCWtwPESb8bwc1ju9DszO1AbhULUOGk1zV8rbJ90O1amxN5Rld+CeYkgvW11OmH3pBsACxKISUZuxFAzbLZR2DwJgyQOJKxQolEjRDxWfCqgmDZDMacU5oASQBSjBdYKkPnHBVH5oMTMPKRcKPOABMy0RAnCcQwSpcLESLzbK1NjHNN8n07JxnAof6B6haeWbBlldqkjnhA5eEx1R3YE/HySjwmRKcX3/lKmtkeFBTbTIIwguXuR7A1uhJFIas7sL3ymKQ2e6fVkK2COPM70ccA1UxU6djG2PYgBN3Gxqb5RO+lVmy0XCcjjwf7irDztjPSUkthWZI0MapBqMh5Wa+zLlqf3WMJEuNOnr4Ql/E4eX/f2eebI+/xOaCloKpLGbbN7+rrR6ViH9XdD6oosfK4FTyEwikjkIUI3ZDN+qMSZOCmH2kXJCw6QvDrlMaZQUZ8iS/01kbErp53Fnru4LiZKQT+e39gS9osGcX+d/yyFJknvD9XskpOLjGfC4ynHCyHJnA87p91W+xVepW93jU/PsskpQJ30OFqUq95CqVS+CYIFlkVU+jPh/09J8qz0Jo5xGyYjPZDLXVfopGYratgiGzlyfVqUGc9gla2IPFXSHdqmbPdv26FSG0poOOAiinzjLCsMz4+faB56FGdujx7JnTszeT+BlVEvV1WlnpYniYNSm7lXdiGMOnyezUjFJ7pKXkZB8XmwX4uC7NNgv/YbsSDKyg==
VazJJkj6HufwcvmT
Listen
